Advertisement
Singapore markets close in 6 hours 6 minutes

  • Straits Times Index

    3,294.47
    +21.75 (+0.66%)
     

  • Nikkei

    38,329.39
    +777.23 (+2.07%)
     

  • Hang Seng

    17,098.07
    +269.14 (+1.60%)
     

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • Bitcoin USD

    66,587.57
    -197.28 (-0.30%)
     

  • CMC Crypto 200

    1,432.53
    +17.77 (+1.26%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Gold

    2,332.00
    -10.10 (-0.43%)
     

  • Crude Oil

    83.32
    -0.04 (-0.05%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • FTSE Bursa Malaysia

    1,567.80
    +6.16 (+0.39%)
     

  • Jakarta Composite Index

    7,168.96
    +58.15 (+0.82%)
     

  • PSE Index

    6,572.46
    +65.66 (+1.01%)
     

Company News For Jan 2, 2020

Zacks Equity Research

  • Shares of Neovasc Inc. NVCN soared nearly 37% after the company announced that it had submitted a premarket approval application to the U.S. Food and Drug Administration for Neovasc Reducer, used in treatment of refractory angina

  • Shares of Viveve Medical, Inc. VIVE jumped 46.5% after the company announced that it has regained compliance with Nasdaq listing rules

  • Shares of Seadrill Limited SDRL rose 7.2% after the company reported that it has received a 3-year contract for AOD II and AOD III, which is expected to be $98 million and $101 million in value

  • Shares of Urovant Sciences Ltd. UROV rose 18.4% after the company reported submission of New Drug Application for Vibegron, used for the treatment of overactive bladder


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Neovasc Inc. (NVCN) : Free Stock Analysis Report
 
Viveve Medical, Inc. (VIVE) : Free Stock Analysis Report
 
Urovant Sciences Ltd. (UROV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research